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ABSTRACT 
 
Swine brucellosis is a zoonotic disease with variable incidence rates in domestic 
and feral populations. It is a serious public health issue due to the potential for spillover 
not only between infected feral and domestic swine but also cattle and humans. Previous 
studies published by our laboratory has demonstrated the cross-protective immunity 
elicited by the S19ΔvjbR live attenuated vaccine in mice against challenge with B. 
abortus, B. melitensis or B. suis, suggesting its potential use as a vaccine against 
multiple Brucella species. To date there is no effective vaccine used to prevent 
brucellosis in swine. This prompted us to study the potential use of S19 ΔvjbR as a 
vaccine candidate in this natural host by evaluating its safety and humoral response in 
pregnant swine. Fifteen pregnant gilts at fifty days of gestation (midgestation) were 
divided into four groups and vaccinated subcutaneously with 1X1010 CFU of either; 1) 
strain S19; 2) S19ΔvjbR encapsulated in alginate microspheres 3) unencapsulated 
S19∆vjbR, or 4) empty capsules as a control. Interestingly, none of the animals 
vaccinated with either S19 or S19∆vjbR aborted or demonstrated any adverse side effect 
associated with vaccination. No bacteria was recovered from any of the tissues examined 
supporting the lack of histopathological changes in major organs either in piglets or in 
gilts. Vaginal swab culture from vaccinated animals showed no bacterial growth on 
Farrell’s agar medium. RBT and IgG iELISA tests were found substantial at 2 week (k= 
0.8) and 4 week (k=0.65) post-vaccination suggesting that RBT can be used during this 
interval as a good tool to confirm the immunization of animals with the different vaccine 
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strains. Different responses of gilts sera against purified vjbR protein at pre-vaccination 
and two week post-vaccination raised the question of specificity of the vjbR as marker 
and its inability to validate DIVA capabilities of the ΔvjbR vaccine candidates.  
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1. INTRODUCTION 
 
Brucellosis is a zoonosis caused by Brucella spp of nearly worldwide distribution 
especially in low and middle income countries [1]. Among the 12 identified species of 
Brucella classified based on preferential host specificity, 3 are highly pathogenic not 
only for their preferred host species but also for humans (Brucella melitensis (sheep and 
goat), Brucella abortus (cattle) and Brucella suis (swine)), and are all associated with 
significant economic losses in different parts of the world [2]. The disease manifests 
differently in animals and humans. Brucellosis in humans is acquired by direct contact 
with animal discharges or consumption of unpasteurized milk products. It is considered a 
debilitating febrile disease with undulant fever as a major symptom, frequently 
accompanied with fatigue, sweats, malaise, chills, weight loss, arthralgia and myalgia 
[3]. Treatment is based on combined antibiotic regimen that can last for up to 6 months 
limiting the ability of patients to work or support their families [4,5]. Without adequate 
treatment, the disease can persist chronically. Several complications can be encountered 
including osteoarticular, cardiovascular, neurological and adverse obstetrical problems 
that can lead to abortion during the first or second trimester of pregnancy [6–9].  
Brucellosis has been associated with occupational exposure in farmers, veterinarians and 
slaughterhouse workers. Brucella infection in animals is characterized by abortion and 
infertility in cattle, sheep, goats, swine and canines [10,11]. This leads to a serious 
problem in the trade of animals and their products causing significant economic losses 
for livestock and kennel breeders [12]. Countries that lack efficient control programs 
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based on quarantine, slaughter and vaccination are the most susceptible to these 
problems. 
Swine brucellosis is encountered in domestic and feral pigs. The disease can be 
transmitted via venereal route with a high risk of spill-over between wild boar and 
outdoor domestic pigs as well as cattle [13]. It is associated with impaired infertility 
manifested by orchitis and epididymitis in boars, production of small litters, and abortion 
in sows that can occur at any stage of gestation [14]. However, if infection with B. suis 
occurs after day 35 of gestation, late abortion is usually observed [15]. There are five 
biovars of Brucella suis [16,17]. Only three of them, including biovar 1, 2 and 3, have 
been known to cause infection in swine [16,17]. Brucella suis biovar 1 and 3 are the 
main biovars that infect swine and have been reported in the United States and Australia 
as the main cause of human brucellosis especially in hunters of feral hogs [18–20]. B. 
suis biovar 2, whose natural carriers are hares, has been isolated from outbreaks in 
Europe from 1999 to 2000 from wild boar [21–23]. This is important due to the potential 
spillover from the feral swine to the domestic outdoor pig herds and the high zoonotic 
risk [21]. Other Brucella species, such as B. abortus and B. microti, may infect swine 
[24–26]. 
Swine brucellosis is the perfect example of the “One Health” paradigm in which 
vaccination represents a key strategy to protect animals and therefore humans [27,28]. 
Along these lines, enhancing veterinary vaccines can considerably reduce the burden of 
Brucella suis leading to improvement of public health [29].  
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Currently, there is no effective vaccine against swine brucellosis. Despite the 
availability of commercial Brucella live attenuated vaccines for cattle and small 
ruminants, their efficacy on domestic pigs is still controversial. Brucella abortus Strain 
19, a spontaneously attenuated smooth B. abortus used since 1941 [30], is highly 
protective in cattle [31]. The major drawback is residual virulence to pregnant animals 
and interference with diagnostic tests due to the production of anti-LPS antibodies in 
immunized animals [2]. Studies of the potential use of S19 in swine have been very 
limited with mixed results in regards to their protective efficacy when animals were 
challenged with Brucella suis wild type [32–34]. Another vaccine that have been studied 
for its potential use in swine is the most recently developed Brucella abortus RB51 
which is a live attenuated rough mutant of B. abortus strain 2308 that replaced S19 for 
the vaccination of cattle in the USA. Safety and efficacy studies in pigs using the RB51 
demonstrated no protection against B. suis challenge in domestic pigs [35]. The only 
commercially available vaccine that is currently employed in swine is the strain 2 (S2) 
[36]. This strain was isolated from an aborted sow in 1953 and attenuated by serial 
passage [37]. Due to residual virulence associated with abortion when administered 
subcutaneously or intramuscularly, the vaccine is currently being administered only 
orally in China [36]. However, the major drawback is the lack of consistent levels of 
protection attributed to non-reproducible immunization doses via this route [38]. Studies 
against wild type B. suis challenge have demonstrated 75% protection in pregnant sows 
when vaccinated under controlled laboratory doses [36]. 
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Recent advances in Brucella abortus vaccine development, outline the promising 
role of live attenuated vaccines via gene deletion or overexpression to enhance immune 
protection [2]. Various virulence factors have been identified, among them is the VirB 
regulon [39,40]. This virulence factor is essential for Brucella to replicate inside 
macrophages and sustain infection [41]. Research in our laboratory has identified 
Brucella spp genes required for virulence and survival via transposon mutagenesis 
[42,43]. Among these genes, vjbR (BMEII1116), encodes a LuxR-like transcriptional 
regulator involved in quorum-sensing, and required for adequate VirB (T4ss) expression 
[44]. VjbR mutants have been proven to be highly effective in inducing protective 
efficacy in different animal species when exposed to wild type Brucella. Our 
laboratories have demonstrated that vjbR mutants can induce cross-protective immunity, 
suggesting its potential use in different animal species against different virulent Brucella 
spp [45,46]. This study evaluates the potential use of live attenuated Brucella abortus 
strain 19 ∆vjbR as a vaccine to be used in swine regardless of their reproductive status. 
S19 ∆vjbR mutants have been demonstrated to be safer than S19 when inoculated in 
different laboratory animals [47,48], however, the protective efficacy is diminished 
compared to S19. To overcome the reduced efficacy, we have previously demonstrated 
that efficacy can be enhanced by delivering the vaccine in a microencapsulated format. 
The vaccine strain is engulfed within an erodible alginate microcapsule containing non-
immunogenic protein designated VpB (Vitelline protein B), that is extracted from the 
eggshell of Fasciola hepatica [49]. The decay of the capsule gradually releases the 
ΔvjbR knockout mutant over a period of 36 days [50]. 
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Based on the promising findings of vaccinating animals with live attenuated 
S19ΔvjbR vaccine strains, we sought in this study to evaluate the safety of S19 ΔvjbR 
vaccine candidates in comparison to S19 in pregnant swine at mid-gestation, period of 
which they are more susceptible to abortion [15]. To monitor for vaccination, a follow-
up of the humoral response was assessed biweekly by Rose Bengal Test (RBT), anti-
Brucella IgM and IgG iELISAs until delivery. Further, purified vjbR protein was 
selected as a serological marker considering its immunodominant characteristic [51] and 
its ability identify Brucella infected humans using serodiagnostic tests [52]. These 
factors prompted the use of purified vjbR protein to differentiate vaccinated gilts with 
ΔvjbR vaccine candidates from those vaccinated with S19 and consequently establish a 
serological test that demonstrates the DIVA capability of the vaccine candidates. 
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2. MATERIALS AND METHODS 
 
2.1. Animals 
 
Fifteen American Yorkshire healthy gilts were obtained from a privately owned 
swine herd in Texas. All gilts were synchronized and artificially inseminated at the same 
time. Upon arrival, all animals were confirmed to be negative for brucellosis. At 50 day 
post-insemination, pregnancy was confirmed via ultrasound. Only pregnant animals 
were included in the study. The animals were housed in an outdoor fenced Biosafety 
Level 2 area with restricted access at the Veterinary Medical Park of Texas A&M 
College of Veterinary Medicine and Biomedical Sciences and acclimated for 1 week 
prior to vaccination. The experimental protocol was approved by TAMU Institutional 
Animal Care and Use Committee (IACUC). 
 
2.2. Construction of the S19 ΔvjbR vaccine candidate 
 
S19 ΔvjbR deletion was engineered and used as a vaccine candidate in a previous 
study [48]. Specifically, for this mutant, the sequence downstream of the vjbR gene was 
amplified from B. abortus 2308 with the primer pair 5′-
GTCTTCGAGGATGTACAATTGGC and 5′-CATCTCGTCTGATCAACATGG. The 
sequence upstream of vjbR was amplified with the primer pair 5′-
GAAGCGCCAAAGTATCGC and 5′-CAGTTGGAAAAGGGCTTTTCCAACCG. 
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These two products were ligated to one another via overlapping PCR with an AscI site 
(New England Biolabs) engineered between the two sequences.  
This product was then ligated to pEX18Ap, and a kanamycin resistance gene was 
inserted within the vector at the unique AscI site. This construct was used for the 
electroporation into S19. Potential marked deletion mutants were kanamycin resistant 
and ampicillin sensitive and were verified by PCR and Southern blotting.  
 
2.3. Preparation of Brucella abortus S19 and S19 ΔvjbR vaccine strains 
 
Brucella abortus S19 (NVSL, Ames, IA) and S19 ΔvjbR were grown separately 
on Tryptic Soy Agar plates (TSA) for 3 days at 37C with 5% (vol/vol) CO2. The 
vaccine strains were harvested from the surface of the plates after 3 days of incubation 
using phosphate-buffered saline (PBS), pH 7.2. The bacteria were resuspended to a final 
concentration of 1 × 1010 CFU/mL based on optical density readings using a Klett meter 
and a standardized light-scattering curve. Actual viable counts were confirmed 
retrospectively by serial dilution, plating, and enumeration.  
 
 
2.4. Preparation of encapsulated B. abortus S19 ΔvjbR vaccine strain 
 
Vaccine preparation was performed as previously described [48]. Briefly, 1 × 
1010 CFU of the B. abortus S19 ΔvjbR was resuspended in 1 ml of MOPS buffer (10 mM 
MOPS, 0.85% NaCl [pH 7.4]) and mixed with 5 ml of alginate solution (1.5% sodium 
alginate, 10 mM MOPS, 0.85% NaCl [pH 7.3]). Extrusion of the suspension through a 
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200-μm nozzle into a 100 mM calcium chloride solution produced spheres that were 
stirred for 15 min by using a Nisco Encapsulator Var V1 (Nisco Engineering AG, 
Zurich, Switzerland). The capsules were then washed twice with MOPS for 5 min and 
further cross-linked with 0.05% poly-l-lysine (molecular weight. 22,000; Sigma) for 10 
min. 2.5 mg of VpB (vitelline protein B [45]) was added to the crosslinking solution. 
After two successive washes, the microspheres were stirred in a solution of 0.03% 
(wt/vol) alginate for 5 min to apply a final outer shell and washed twice with MOPS 
before storage at 4°C. 
 
2.5. Cloning, expression and purification of the vjbR recombinant protein  
 
The vjbR BMEII1116 open reading frame (ORF) was amplified by PCR from 
Brucella melitensis 16M then cloned into Champion pET SUMO N-terminal 6xhist-
tagged vector expressed in E. coli BL21. Glycerol stock of E. coli carrying vjbR protein 
was cultured in 10ml of LB broth overnight at 37C. Plasmid DNA was isolated 
according to the manufacturer instructions (E.Z.M.A Plasmid DNA Mini kit (Omega 
bio-tek)) and quantified using Nanodrop spectrophotometer. Sequencing of the plasmid 
DNA (~400 ng/ sample) was done using pET Sumo vector forward sequencing primer 
and using vjbR 3’ end reverse primer separately. The expression of the recombinant 
protein was assessed by performing an SDS-PAGE to the bacterial lysate containing the 
protein. The vjbR protein was purified from the BL21 lysate expressing the fusion 
protein by nickel column affinity chromatography using the ProBond™ Purification 
System Kit (Invitrogen) and analyzed by SDS-PAGE. The protein was dialyzed against 
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10 mM Tris, pH 8.0, 0.1% Triton X-100 overnight at 4°C to remove the urea and protein 
concentration was measured using Pierce BCA protein assay kit (Thermofisher).  
VjbR protein was also expressed in yeast and antibody against vjbR was raised in 
rabbit (MyBiosource, San Diego, USA) to use it for the characterization of the purified 
protein.  
 
2.6. Characterization of the vjbR protein via liquid chromatography–mass spectrometry 
  
Polyacrylamide gel containing vjbR protein stained with traditional Coomassie 
stain was transferred to Protein Chemistry Laboratory of Texas A&M University. An 
individual specific band of ~40 kDa was excised then reduced from disulfide bonds and 
alkylated with iodoacetamide prior to digestion. After tryptic digestion, the sample was 
analyzed on a ThermoFisher LTQ linear ion trap mass spectrometer using nano-LC 
peptide separations [53]. 
 
2. 7. Determination of vjbR like protein homology in other bacteria and assessment of 
crossreactivity 
 
The vjbR protein sequence was subjected to protein-protein BLAST (Basic Local 
Alignment Search Tool; blastp) analysis from the NCBI website to identify sequence 
similarity of the vjbR protein with other organisms via sequence alignments.  
Ochrobactrum anthorpi, Pseudomonas aeruginosa and E. coli strain K-12 were selected 
for their close similarities with the vjbR protein to assess for crossreactivity. Colonies of 
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Ochrobactrum anthorpi were grown on TSA plates and Pseudomonas aeruginosa and E. 
coli strain K-12 were grown on Luria Bertani (LB) agar plate at 37°C for 48 hours. 5 mL 
of PBS was added to each plate and mixed with the bacteria and then collected into 10 
mL tubes. The suspension was centrifuged for 5 minutes at 5000 rpm then the 
supernatant was discarded. Guanidine lysis buffer was added to the pellet for 10 minutes 
shaking then subjected to sonication. Then, the solution was centrifuged for 10 minutes 
at 13000 rpm. Supernatants were collected and subjected to SDS-PAGE followed by 
transfer into nitrocellulose membrane for western blot analysis. Pre-vaccinated gilt sera 
from S19 and S19 ΔvjbR encapsulated were used as primary antibodies (1:5000) for the 
detection of any cross-reactivity with Ochrobactrum anthorpi, Pseudomonas aeruginosa 
and E. coli strain K-12 lysates. 
 
2.8. Immunization of pregnant gilts 
 
Confirmed pregnant gilts by ultrasound at 50 days of gestation were randomly 
distributed into 4 groups and inoculated subcutaneously (SQ) in the scapular area with a 
single dose containing 1x1010 CFU of either 1) S19 (n=4), 2) encapsulated S19ΔvjbR 
(n=4), 3) unencapsulated S19ΔvjbR (n=4), or 4) control (n=3). All animals were housed 
individually and no direct contact between animals of different groups was allowed.  
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2. 9. Clinical evaluation 
 
2. 9. 1. Monitoring for adverse side effects associated with vaccination 
 
Prior to vaccination and until delivery, gilts were monitored twice a day for any 
adverse side effects associated with vaccination including abortion, adverse reactions at 
the site of injection, abnormal vaginal discharges, and fever. Rectal temperature of 
pregnant gilts was measured daily using a digital thermometer to assess any abnormal 
temperature fluctuation. 38.8ºC (± 0.3°C) was considered the normal body temperature 
threshold for gilts [54].  
 
2. 9. 2. Vaginal shedding of the vaccine strains 
 
Screening for vaginal shedding of the different vaccine strains was performed 
biweekly on all animals. Vaginal swab specimens were obtained individually from all 
gilts and plated onto Farrell’s agar medium (OXOID) for bacterial isolation. Plates were 
incubated at 37°C and monitored daily for up to 30 days. 
 
2. 9. 3. Gross and histopathological evaluation of gilts 
 
Within the first 3 days post-delivery, all sows were euthanized via pentobarbital 
overdose and necropsied for the detection of any gross lesions associated with 
vaccination. Multiple tissue sections including: spleen, liver, lung, uterus, placenta, pre-
scapular, mammary, inguinal and mesenteric lymph nodes were collected from sows and 
transferred into histology cassettes. Tissue sections were fixed in 10% buffered formalin, 
paraffin embedded and section stained with hematoxylin and eosin (H&E). Histological 
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changes between different treatment groups were microscopically assessed by a board 
certified veterinary anatomic pathologist.  
 
2. 9. 4. Determination of bacterial colonization in tissues from gilts 
 
Colonization of maternal tissues was assessed by culture after delivery. Spleen, 
liver, lung, uterus, pre-scapular, mammary, inguinal and mesenteric lymph nodes were 
removed and weighed. 1gr of tissue was homogenized and resuspended in 1 mL of PBS 
using Omni Prep Multi-Sample Homogenizer (Omni-inc, GA, USA). Serial dilutions 
were prepared and 100 μL of each sample was plated onto TSA (Tryptic Soy Agar) and 
Farrell’s agar medium (OXOID), and incubated up to 30 days at 37C with 5% (vol/vol) 
CO2. The experimental limit of detection was determined to be 10 CFU per gram of 
tissue.  
 
2. 9. 5. Gross and histopathological evaluation of piglets 
 
Piglets from all gilts were euthanized within the first hours of birth. All the 
piglets were necropsied and evaluated for gross lesions. Lung float test was conducted to 
assess fetal viability upon birth. Tissue sections of spleen, liver, lung and umbilical cord 
were fixed in 10% buffered formalin, paraffin embedded and section stained with 
hematoxylin and eosin (H&E). Histological changes between different treatment groups 
were microscopically assessed by a board certified veterinary anatomic pathologist. 
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2. 9. 6. Vertical colonization of piglet tissues 
 
In an effort to determine if the vaccine strains were capable of colonizing piglet 
tissues during gestation, sections of spleen, lung, liver, kidney, pylorus and umbilicus of 
all piglets were collected within the first 12 hours of delivery. 1 gr of tissue from each 
organ was cultured in TSA (Tryptic Soy Agar) and Farrell’s agar medium (OXOID) 
after homogenization in 1 mL of PBS using Omni Prep Multi-Sample Homogenizer 
(Omni-inc, GA, USA) and incubated up to 30 days at 37C with 5% (vol/vol) CO2.  The 
experimental limit of detection was determined to be 10 CFU per gram of tissue. All 
cultures were done in duplicate. 
 
2. 10. Serological responses in pregnant gilts 
 
2. 10. 1. Rose Bengal Test (Brucellosis Card Test) 
 
Approximately 10 mL of blood was collected from each gilt into tubes without 
anticoagulant prior to vaccination and at 2, 4 and 6 week post-vaccination. Blood was 
centrifuged at 2000 x g for 15 min to collect serum and stored at -20°C. Serum 
agglutination against Brucella antigen was performed using the brucellosis Card Test 
(Becton Dickinson Microbiology Systems for USDA/APHIS National Veterinary 
Services Laboratory, Ames, Iowa). 30 μL of sera from immunized animals was added to 
an equal amount of Rose Bengal antigen into a brucellosis diagnostic card and mixed 
thoroughly with a stick. A scale was developed to categorize the degree of agglutination 
and consisted of: 1) ++++/+++ strong agglutination, 2) ++ mild agglutination, 3) + weak 
agglutination and 4) - no agglutination 
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2. 10. 2. Determination of anti-Brucella IgMs and IgGs 
 
Indirect Enzyme Linked Immunosorbent Assay (iELISA) to detect anti-Brucella 
specific immunoglobulin G (IgG) and M (IgM) was performed prior to vaccination and 
at 2, 4 and 6 weeks post-vaccination serum samples in polystyrene microtiter plates 
(Maxisorp, NUNC). 96 well plates were pre-coated overnight at 4°C with 25 μg/well of 
Brucella abortus 2308 heat killed/sonicated lysate as antigen. The next day, plates were 
washed with PBS-T to remove unbound proteins, blocked with 0.5 ml of blocking buffer 
(0.25% [wt/vol] bovine serum albumin), and then incubated with sow sera samples 
(dilution 1:500) in the same blocking buffer for 1 h at room temperature. After extensive 
washing to remove unbound antibody, the secondary antibody (peroxidase labeled goat 
anti-swine IgG or IgM) was added at a dilution of 1:1000, and incubated for one hour. 
At the end of the incubation period, plates were washed again, and horseradish 
peroxidase substrate was added, followed by incubation for 15 min. The reaction was 
stopped by adding 50 μl of 0.5 M NaOH, and the absorbance was measured at 450 nm 
(A450). All assays were performed in triplicate. The results are represented as the mean 
of triplicate wells for each sample. 
 
2.11. Immunodetection of the vjbR his-tagged recombinant protein expressed in E. coli 
and in yeast 
 
The expression of vjbR recombinant protein was examined by western blot. An 
SDS-PAGE with the purified vjbR expressed in E. coli, the E. coli lysate containing the 
vjbR gene in the plasmid as a positive control and E. coli without plasmid as a negative 
control, were transferred into a nitrocellulose membrane for 120 min (100 V). Another 
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SDS-PAGE using the histagged vjbR expressed in yeast was run separately (results not 
shown). After incubation with 5% nonfat dry milk for 2 hours, the membranes were 
washed 3 times with TTBS 0.2% (5 min each wash) then incubated with mouse HRP 
anti-histag antibody (1:20000) shaking in the dark at +4 ºC overnight.  
The following day, the nitrocellulose membrane was washed 6 times with TTBS 
0.2% and then incubated with Clarity™ Western ECL Blotting substrate for 5 min).  
 
2. 12. Polyclonal anti-vjbR antibody production 
 
One rabbit was immunized with the purified vjbR expressed in yeast for anti-vjbR 
antibody production. After three boosters of the vjbR protein, the serum was collected 
and used as primary antibody (1:5000 dilution) after transfer of the vjbR protein into a 
nitrocellulose membrane. Peroxidase labeled anti-rabbit total IgG (1:10000) was used as 
secondary antibody. Clarity™ Western ECL Blotting substrate (Bio-Rad, CA, USA) was 
used for detection. Images were analyzed using EMBL ImageJ software. A band size of 
~40 KD expressing the vjbR was observed. 
 
2. 13. Evaluation of the potential use of the vjbR protein as a DIVA marker 
 
The ability of differentiating vaccinated animals with S19 ΔvjbR from those 
vaccinated with S19 was assessed by a western blot based assay using the vjbR as 
antigenic marker. 
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2. 13. 1. Western blot based assay 
 
The vjbR protein expressed in E. coli was subjected to 12% SDS-PAGE followed 
by transfer into nitrocellulose (NC) membrane using wet electroblotting system (Bio-
Rad, CA, USA). Sera from all pre-vaccinated and 2 week post-vaccination gilts were 
used as primary antibodies. Peroxidase labeled goat anti-swine total IgG (KPL, MA, 
USA) was used as secondary antibody. Multiple serum titrations of primary and 
secondary antibodies ranging from 1:2500 to 1:20000 were tested and finally 1:5000 
dilution for primary antibodies and 1:10000 for secondary antibody were selected for 
downstream experiments. Positive control was included and consisted of the rabbit anti-
vjbR primary antibody (MyBiosource, CA, USA) (1:5000) and Peroxidase labeled anti-
rabbit total IgG (KPL, MA, USA) was used as secondary antibody (1:10000). Clarity™ 
Western ECL Blotting substrate was used for detection. Presence of vjbR band (~40 KD) 
in S19 vaccinated animals and absence of vjbR band in S19 ΔvjbR was expected. 
 
2.14. Statistical analysis 
 
All analyses were performed using the GraphPad Prism 6.0 software (San Diego, 
CA, USA) and P values <0.01 were considered significant. The non-parametric one-way 
analysis of variance (ANOVA) test was used to compare between litter size temperature 
of different groups and Tukey’s multiple comparisons was used to generate P value. The 
non-parametric one-way analysis of variance (ANOVA) test was used to compare 
between body temperature of different groups and Dunn’s multiple comparisons was 
used to generate P values for selected mean comparisons. The cut-off value of the 
   17 
iELISA (0.4) was calculated as three standard deviations plus the average of negative 
controls. The two-way analysis of variance (ANOVA) test was used for the anti-Brucella 
IgG and IgM experiments followed by Tukey’s multiple comparisons test. Correlation 
between the iELISA total IgG and the Rose Bengal Test results was evaluated by 
Pearson’s correlation coefficient. Kappa () statistic was used to establish the degree of 
concordance between the two assays. 
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3. RESULTS 
 
3. 1. Clinical evaluation in gilts 
 
3. 1. 1. Monitoring of abortion associated with the use of S19 ΔvjbR and S19 vaccine 
candidates 
 
One of the main drawbacks associated with vaccination using LAV is the 
induction of abortion in pregnant animals [55–59] . In order to determine if vaccination 
with either S19 or S19 ΔvjbR induced abortion, animals were vaccinated subcutaneously 
(SQ) at a dose of 1X1010 CFU with the different vaccine candidates at mid-gestation and 
were monitored daily until farrowing. Interestingly, all the animals farrowed normally 
regardless of the treatment group with no evidence of abortions or preterm delivery 
observed (Table 1).  
The average litter size per group was 12 animals in both vaccinated S19 and S19 
∆vjbR encapsulated groups, 11 animals in S19 ∆vjbR unencapsulated group and 12 
animals in the control group. There was no significant difference in litter size among 
different groups (p-value 0.9) suggesting that vaccination did not influence litter size. 
 Delivery in all gilts was characterized by the normal delivery of healthy piglets 
among all groups. Post-partum period was characterized by behavioral changes in gilts 
manifested by rejection of newborns and deaths by crushing among different groups. 
In order to distinguish between traumatic deaths and stillbirths, lungs of all dead 
piglets were submitted to lung test by embedding a part of lung from each dead piglet 
into water [60]. 16.66% of piglets from S19 and control groups were confirmed as 
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stillbirths (Table 1). Interestingly, no stillborns were detected among S19 ∆vjbR 
encapsulated and unencapsulated groups. So far, the significance of this finding does not 
relate stillbirths to vaccination since the highest mortality including stillborn piglets was 
observed among the control group. 
 
3. 1. 2. Clinical examination and body temperature determination  
 
Gilts were monitored daily to evaluate any adverse side effects associated with 
vaccination. Throughout the study period, no adverse effect associated with behavior, loss 
of body weight, or local inflammation response at the injection site were observed among 
the different groups (data not shown).  
Assessment of body temperature was performed daily via rectal route. Fever was 
considered to be a temperature above 38.8°C [54]. No significant changes in body 
temperature were observed between groups regardless of the vaccine formulation (Fig.1). 
Although not significant, decrease in body temperature in all groups was observed 
between 2 and 3 week post-vaccination which corresponded with low environmental 
temperatures of 9 to 8ºC (Fig. 1). 
 
3.1. 3. Vaccine shedding in vaginal secretions 
 
A major drawback of the use of LAV is the possibility of the vaccine to be 
excreted into the environment, serving as potential source of contamination and infection 
of naïve animals or non-target species [61].  
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In an attempt to determine if any of the vaccine formulations were shed into the 
environment through vaginal secretions, vaginal swabs cultures were done biweekly 
starting from the day of vaccination until delivery. There was no growth on Farrell’s 
agar medium in any of the animals regardless of the vaccine formulation (Table 2). 
 
3. 1. 4. Determination of bacterial colonization in gilts 
 
The kinetics of bacterial clearance, at the time of delivery was evaluated by 
tissue culture. Liver, lung, spleen, lymph nodes, uterus and placenta were collected after 
euthanasia of all gilts within 5 days of the delivery. Interestingly, no bacteria was 
recovered from any of the tissues examined after delivery (Table 3). 
 
 
3. 1. 5. Gross and histopathological evaluation of major tissues in vaccinated gilts 
 
Previous studies in the mouse model using Brucella abortus S19 LAV have 
demonstrated that major organs can display inflammatory responses consequent to 
vaccination [62].  
In mice, vaccination with S19 is characterized by the induction of splenomegaly, 
considered to be a classic sign of brucellosis. Mice inoculated with S19 ΔvjbR do not 
cause this inflammatory response [47,48]. Based on these observations, determination of 
any histopathological changes secondary to vaccination was assessed in major organs of 
vaccinated gilts.  A full necropsy was conducted in all gilts within the first five days 
post-delivery. Tissue sections consisting of liver, lung, spleen and uterus were collected, 
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formalin fixed, paraffin embedded and double blinded and analyzed by a board certified 
anatomic pathologist.  
No significant histopathological changes were observed in all major organs 
(spleen, liver, lung, uterus) of gilts regardless of the treatment (Fig. 2).   
 
3. 2. Serological responses in pregnant gilts 
 
3. 2. 1. Rose Bengal Test (Brucellosis Card Test) 
 
The humoral response elicited by the vaccination of gilts was evaluated biweekly 
over the course of 6 weeks. The RBT was used as a rapid screening test for vaccination. 
  A summary of the results is presented in table 4. Serum samples from control 
animals and at pre-vaccination and control were negative. At 2 week post-vaccination, the 
agglutination response was the highest among all groups regardless of the formulation. 
There was no statistical difference between the different vaccine candidates. Starting at 4 
week post-vaccination, the agglutination response started to decrease in all groups and 
varied between mild or weak agglutination, with only 2 animals from the S19 ΔvjbR 
unencapsulated still remained as strong positives. At 6 week post-vaccination, regardless 
of the treatment, all gilts became serologically negative.  One gilt vaccinated with 
unencapsulated S19 ΔvjbR remained negative during the whole period of the experiment 
and later confirmed to have seroconverted via ELISA.   
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3. 2. 2. Determination of anti-Brucella IgM and IgG 
 
To further elucidate the kinetics of the humoral response elicited by the 
inoculation of different vaccine strains, indirect ELISAs were conducted to measure the 
anti-Brucella IgM and IgG OD values using B. abortus 2308 heat killed lysate as the 
coating antigen. Anti-Brucella IgM and IgG OD values were negative in all groups prior 
to vaccination. At 2 week post inoculation, the anti-Brucella IgM in all vaccinated 
animals was the highest throughout the course of the study. Starting from 4 week post 
vaccination, the levels started to decrease in all animals and significant difference was 
noticed between S19 and S19 ∆vjbR encapsulated, S19 ∆vjbR unencapsulated and S19 
∆vjbR encapsulated but also with the control group (P<0.01). By 6 week post-
vaccination there was no significant difference among all treatment groups and the 
control (Fig 3, upper panel). The kinetics of the anti-Brucella IgG levels was similar to 
that observed in IgM.  The highest OD value was observed at 2 week post-vaccination 
among all vaccinated groups and no statistical difference was observed between 
vaccinated groups while the control group remained negative and statistically significant 
in comparison to them (P<0.01). At 4 week post inoculation, the levels of IgG in 
vaccinated animals had already started to decrease and remained statistically similar 
between each other but were still statistically significant compared to the unvaccinated 
group (Fig. 3. Lower panel). At 6 week post-vaccination, all gilts were negative (P value 
compared to control). As expected, the seronegative animal from S19 ∆vjbR 
unencapsulated group via RBT was confirmed to be positive by iELISA. The kinetics of 
both anti-Brucella IgM and IgG demonstrated a transient, short humoral response in 
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swine after vaccination regardless of the formulation which is different from what it is 
typically observed in mice, cattle or red deer inoculated with S19 or S19∆vjbR.  
The variation of the results obtained between the RBT and IgG iELISA at 
different time points prompted us to evaluate the correlation between the two techniques. 
The cutoff value for the indirect ELISA was calculated as three standard deviations plus 
the average of negative controls and it was equal to 0.4. The kappa value and the 
likelihood estimates were calculated using a Bayesian model [64].  
Seroconversion of the vaccinated gilts at 2 week post-vaccination was at its 
highest by agreement of the iELISA and RBT (k= 0.8). The agreement between RBT 
and IgG iELISA tests was found substantial at 2 week (k= 0.8) and 4 week (k=0.65) 
post-vaccination (Table 5) suggesting that RBT can be used during this interval as a 
good tool to confirm the immunization of animals with the different vaccine strains.  
During 6 week post-vaccination time point, the agreement between the two 
techniques was poor. This can be related to individual vaccinated animals that 
demonstrated higher OD values than the threshold (0.4) during that period (Fig. 3). 
 
3. 3. Clinical evaluation in piglets 
 
3. 3. 1. Vertical colonization of piglets 
 
Previous studies have demonstrated that Brucella LAV candidates can cross the 
placenta and colonize fetal tissues resulting in the dissemination of the vaccine strains 
into the environment after delivery or abortion [65]. Vertical transmission of the vaccine 
strains to the offspring and colonization of different tissues of piglets was assessed by 
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culture of homogenized major tissues. Liver, spleen, lung, umbilicus, kidney and gastric 
contents were cultured. The lung and the gastric contents were included in this study, 
since these are two of the most common tissues to be colonized by Brucella in fetuses 
[18].  
Regardless of the formulation or vaccine strain, there was no evidence of tissue 
colonization (limit of detection is 10 CFU/gr) in the samples analyzed. (Table 6).  
 
3. 3. 2. Gross and histopathological evaluation of tissues from piglets 
 
A complete gross and histopathological evaluation in all piglets was conducted in 
all piglets. A total of 181 piglets were subjected to analysis. Samples consisted of liver, 
lung, spleen, umbilicus, kidney and stomach. Interestingly, there were no significant 
changes in any of the groups and major organs commonly affected in the case of 
brucellosis in newborns such as umbilicus, lung and liver were unremarkable (Fig. 4).  
Fetal deaths observed following farrowing and suspected to be associated with 
traumatic events were confirmed on gross and histopathological examination. In such 
cases, the presence of acute hemorrhage was consistently observed.  
In the cases of stillbirths (total of 3), there was no evidence of an inflammatory 
or infectious process ongoing in these fetuses and were considered to be unrelated to the 
vaccination. Two of the stillborns observed were in the control, non-vaccinated group.  
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3. 4. Expression, purification and characterization of the vjbR fusion protein 
 
The expression of the histagged vjbR protein was obtained after the induction of 
E. coli containing the Champion ™ pET SUMO plasmid (ThermoFisher scientific, NY, 
USA) with 1 mM IPTG. Following cell lysis, the vjbR fusion protein was purified 
according to the manufacturer instructions (ThermoFischer, NY, USA) and dialyzed 
against 10 mM Tris, pH 8.0, 0.1% Triton X-100 overnight at 4°C to remove the urea 
from the eluted buffer.  
The concentration of the purified vjbR recombinant protein was measured via 
Pierce BCA protein assay (USA). The purified vjbR protein expressed in E. coli was 
subjected to 12% SDS-PAGE and vjbR band of around 40 kDa was excised for liquid 
chromatography-mass spectrometry (LCMS) to confirm the identity of the protein.  
Scaffold Viewer software was used to compare mass spectrometry features to the 
database of the predicted protein (HTH-type quorum sensing-dependent transcriptional 
regulator vjbR). The results demonstrated a peptide coverage of 38% and vjbR was 
identified by 19 unique spectra and 9 unique peptides. 
 
3. 5. Immunodetection of the vjbR protein 
 
Anti-His-tag monocolonal antibodies were used for detection of histagged 
recombinant vjbR protein expressed in E. coli in comparison with appropriate controls. 
Positive control constituted by crude E. coli containing the plasmid expressing the vjbR 
and a lyste of E. coli without any plasmid serving as negative control were used (Fig. 5 
A). Anti-histag monoclonal antibody detected the presence of the histidine tag vjbR 
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fusion protein band (〜40 kDa) in both purified protein fraction as well as crude lysate 
of E. coli expressing vjbR but not in E. coli lysate lacking the vjbR expression (Fig. 5 A). 
 Similarly, the purified vjbR protein expressed in E. coli exposed to the rabbit 
anti-vjbR polyclonal antibody reacted to the same band size 〜40 kDa (Fig. 5 B). Hence, 
we successfully characterized the vjbR protein with these two methods and these 
findings are compatible with the ones of the LC-MS. 
 
3. 6. Evaluation of the potential use of the vjbR protein as a DIVA marker 
 
3. 6. 1. Reactivity of gilt sera using western blot 
 
Sera from all Brucella-free gilts at pre-vaccination (RBT and iELISA results) and 
sera from vaccinated groups and control group at 2 week post-vaccination were tested in 
Western blotting for reactivity with recombinant vjbR expressed in E. coli. Pre-
vaccinated Brucella-free gilt sera from different groups elicited faint to strong 
unexpected immunoreactivity to the vjbR protein expressed in E. coli. Similar results to 
gilt sera at pre-vaccination were observed at 2 week post-vaccination by reacting non-
specifically with the vjbR recombinant protein band (Fig. 6). Several titrations of gilt 
sera as well as anti-swine total IgG were used, however the non-specific binding of sera 
with the vjbR protein remained present. 
 
 
   27 
3. 6. 2. Immunodetection of vjbR like protein reactivity with pre-vaccinated gilt sera 
 
In an effort to understand the non-specific reactivity of gilt sera to the vjbR protein, 
analogy of the vjbR was investigated in different bacteria using NCBI sequence BLAST. 
BLASTp of the vjbR protein sequence revealed 79% homology with Ochrobactrum 
anthropi, 29% with Pseudomonas aeruginosa and 28% homology with E. coli K-12. Sera 
from animals that demonstrated a strong cross-reactivity with vjbR from different pre-
vaccinated groups (S19 and S19 ∆vjbR encapsulated) were subjected to western blot 
analysis using lysates from these bacteria. Despite sharing variable homology with the 
vjbR, none of the animals demonstrated reactivity to the bacterial lysates of the 
correspondent organisms. Additionally, the rabbit anti-vjbR antibody did not react with 
any of the lysates (Fig. 7), ruling out the fact that none of that have the entire vjbR 
sequence. 
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4. SUMMARY AND CONCLUSIONS 
 
 
 
Swine brucellosis is a zoonotic infectious disease caused naturally by Brucella 
suis [3] and experimentally by Brucella abortus [66]. The United States is free from the 
disease in domestic swine contrarily to feral swine which is a reservoir of the disease and 
represents an increasing risk of spill-over [67,68]. Considering the expanding number of 
the wild swine population as well as the potential for spill-over to domestic swine or to 
cattle [69,70], the need of protecting domestic swine especially outdoor domesticated 
swine  is necessary. Serious economic loss will be faced if the domestic swine industry 
is affected by brucellosis [17].  
Vaccination has demonstrated to be an efficacious way to control the disease and 
Brucella live attenuated vaccines have been broadly used in different species [62]. 
Although the B. abortus S19 vaccine played a key role reducing the disease in cattle [2], 
major drawbacks of  inducing abortion in pregnant animals [55] and difficulties in 
discriminating vaccinated from infected animals via serological tests [2] limited the use 
of B. abortus S19 vaccine in the USA. However, worldwide S19 is still being used as an 
effective way to limit the burden of brucellosis [30]. Currently there is no commercially 
available vaccine to control swine brucellosis in the USA or elsewhere except the B. suis 
S2 vaccine which is only being used in China [36]. Thus, there is a critical need to 
develop a vaccine that will not only prevent the disease but also nullify major drawbacks 
like abortions, excretion of vaccine strains to the environment via body secretions like 
milk, urine and vaginal discharges but also vertical transmission to the offspring.  
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Type IV Secretion System (T4SS) are multiprotein complexes identified in 
several Gram-negative bacteria such as Brucella spp. and essential for their 
pathogenicity [73]. The Type IV Secretion System (T4SS) is encoded by the virB operon 
which is a key virulence factor [39]. The jbR, a LuxR family regulator, is known to 
regulate virB expression [74] and has an important role in the virulence and survival of 
Brucella in the mouse model [45]. Thus, a knock-out vjbR mutant vaccine (∆vjbR) to 
attenuate organism virulence and reduce the possibility of inducing disease was 
developed by our laboratories that proved to confer a strong protective immune response 
against wild type challenge [48]. In order to enhance the efficacy of the ∆vjbR mutant 
vaccine, microencapsulation was established making it a potential option for a sustained 
and controlled vaccine delivery system [50]. Considering the promising results of the 
S19 ∆vjbR vaccine candidate in the mouse model [48], we investigated the potential use 
of the mutant vaccine under two different formulations, encapsulated and 
unencapsulated, in comparison with the Brucella abortus S19,  in a natural host  model 
to evaluate the safety of both vaccines. 
As swine is the preferred host of B. suis [3], it is important to mention that the 
CDC and the USDA classifies B. suis as a select agent and it is prohibited to use this 
strain in BSL-2 facilities [75]. This major reason oriented the hypothesis of using B. 
abortus as another Brucella specie that can be used in BSL-2, but is also known to cause 
infection in swine [66]. Since B. abortus S19 is part of attenuated strains that is excluded 
from the Select Agent list and can be used under BSL-2 conditions not only 
experimentally but potentially during vaccine manufacturing [33,34], we sought to 
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evaluate the clinical safety of subcutaneous injection of live attenuated B. abortus S19 
∆vjbR at mid-gestation in pregnant gilts with a single dose of 1x1010 CFU per animal in 
comparison with B. abortus S19 commercial vaccine. In fact, during the early stage of 
the development of a live attenuated vaccine, one of the requirements is the 
demonstration of safety of any vaccine candidate [76]. 
Abortion is one of the major parameters to consider while evaluating the safety 
of a vaccine candidate for brucellosis. Abortion caused by natural B. suis infection in 
swine has been described at late gestation, if infection occurs after 35 days of pregnancy 
[15]. Vaccination with S19 has only been described in a study conducted in an endemic 
farm with brucellosis in 1948, during which abortions occurred while vaccinating 
pregnant sows with S19. Therefore, it is not clear whether abortion was due to 
vaccination with S19 or to a natural exposure. Consequently, we expected to see 
abortion in S19 vaccinated animals, as reported earlier in other species different than 
swine [55,77–80]. It is widely known that S19 induces abortion in pregnant cattle and 
bison during pregnancy [55,56,81]. In fact, abortion was reported while vaccinating 
adult pregnant cattle with S19 at a rate of 22% with 5.8 × 109 CFU/ animal [30,82]. Even 
a reduced dose of 3.0 × 108 organisms was able to induce abortions among pregnant 
cows vaccinated subcutaneously with S19 [79]. 58% of pregnant bison cows between 
90-120 days of pregnancy were seen to abort starting from 60 days post-vaccination with 
5.3 × 108 CFU of Brucella abortus S19 [55]. Additionally, abortion was seen following 
subcutaneous immunization of pregnant reindeer with 1.2 × 108 CFU of Brucella 
abortus S19 [77,83]. In the present study, vaccination of pregnant gilts with a high dose 
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of 1× 1010 CFU/ animal of either S19 or with S19 ∆vjbR did not induce abortion among 
all animals contrarily to other species (Table 1). Interestingly, similar results of lack of 
abortion were described while vaccinating pregnant longhorn antelopes with the same 
dose of Brucella abortus S19 used in this study [80]. Behavioral change among all 
primiparous gilts used in this study was observed after farrowing causing traumatic post-
partum deaths in piglets. This can be related to the susceptibility of primiparous to post-
farrowing stress reflected by maternal infanticide of the gilt ranging from crushing or 
overlaying to aggressive biting of the offspring [84–86] and it is not considered to be a 
consequence of vaccination. Stillbirths evidenced by the lung test [60] were described 
among piglets of vaccinated gilts with S19 as well as the control group suggesting that 
this side effect is not related to vaccination. In fact, under normal conditions, stillborn 
piglets increase when they are born from primiparous gilts [84–86]. Since induction of 
abortion or adverse pregnancy outcomes were not observed in any of the vaccination 
groups, efficacy studies that include the potential use of S19 or S19∆vjbR in swine is the 
next logical step towards the development of such a vaccine.   
Undulant fever is one of the major symptoms of Brucella infection in humans 
[87]. Not only natural infection but also exposure of human to LAV Brucella abortus 
S19 is characterized by an undulant fever. In fact, 53% of vaccine-manufacturing 
laboratory employees in Argentina demonstrated an undulant fever as a major symptom 
after accidental exposure to Brucella abortus S19 vaccine [88]. However, fever has not 
been well investigated in animal brucellosis. In a recent study, an increase in body 
temperatures was observed in pregnant heifers within 1 to 2 days post-vaccination with 
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Brucella abortus S19 and it returned to normal right after that until calving [89]. Also, 
ewes vaccinated with Brucella abortus S19 demonstrated a rise of body temperature that 
reached 41.1oC [90]. To the best of our knowledge, this is the first study investigating 
body temperature fluctuations and fever as a potential side effect related to vaccination 
in swine. In this study, we monitored daily body temperature of gilts and we did not 
detect fever in any animals throughout the duration of vaccination (Fig 1). Gilts body 
temperature was monitored via rectal temperature and the threshold of the maximum 
normal temperature was set at 38.8oC [54]. It has been demonstrated by our study that 
vaccination with S19 or S19 ∆vjbR did not elicit any fever and body temperature 
remained normal and statistically insignificant while comparing them to the control 
group, suggesting that vaccination with S19 or S19∆vjbR is not associated with fever in 
swine. Whether it is a predictor of abortion or not, is yet to be elucidated since none of 
the animals aborted in this study. Although a decrease of body temperature within the 
normal range was observed during 2 and 3 week post vaccination below, we were able to 
associate it with a decrease in environmental temperature during the study since animals 
were housed outdoors.  
Brucellosis is characterized by excreting the bacteria to the environment through 
secretions for instance milk, urine, or vaginal discharges [91,92]. Shedding of vaccine 
strains in those secretions is one of the most important parameters to consider while 
developing a vaccine, since contamination of the environment including water resources 
and pastures could potentially pose a risk to other non-target species residing in the same 
premises including wildlife and humans. In our study, the investigation of the potential 
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excretion of the vaccine strains in vaginal swabs was assessed. Vaginal swabs were 
chosen because animals were pregnant and it has been shown that reproductive tissues 
are often heavily infected with Brucella spp and can be excreted in vaginal mucus [93–
95]. For instance, a previous report described shedding of Brucella abortus S19 vaccine 
strain in vaginal mucus of heifers [96]. Also, Brucella abortus S19 was isolated from a 
vaginal swab specimen after 51 days from vaccination of a reindeer with the same 
vaccine strain [77]. In swine, vaginal shedding was only described in an animal 
inoculated experimentally with Brucella abortus wild type via the subcutaneous route 
[66]. In this study, the assessment of vaginal secretions of S19 and S19 ∆vjbR was 
established during early weeks of vaccination until 6 week post-vaccination. None of the 
vaccinated animals shed any vaccine strains in the vagina at any time point to detectable 
levels.  
Brucellosis is accompanied by colonization of major tissues [97,98] and 
considered as an occupational disease that can affect workers such as butchers in close 
contact with animal organs. Thus, we wanted to investigate if the vaccine strains were 
still circulating in different organs after delivery which can represent a potential risk to 
humans while handling carcasses of vaccinated animals. At 7 week post-vaccination, the 
vaccine strains were not isolated from any of the major tissues of gilts suggesting that 
both S19 and S19∆vjbR strains are not present or below the limit of detection in gilts by 
7 week post vaccination and that S19, S19∆vjbR encapsulated and S19∆vjbR 
unencapsulated vaccine candidate are safe for swine carcass handlers.  
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Major expected lesions that can affect animals either with Brucella wild type or 
S19 are placentitis, endometritis, granulomatous hepatitis and splenomegaly [48,99]. We 
corroborated the clearance results with unremarkable histologic findings of major tissues 
of gilts.  
Aborted fetuses as well as infected offspring are not only hazardous to humans 
but also to the environment. This serious issue needs to be considered while vaccinating 
animals with LAV. Vaccination of pregnant cattle with Brucella abortus S19 results in 
vertical transmission to fetuses and the S19 vaccine strain can be commonly isolated 
from gastric contents of aborted products [55].  In swine, transplacental transmission 
was described in naturally infected sows [12,100] and Brucella Suis S2, the only LAV 
available against swine brucellosis in China, is known to induce abortion while 
administered SQ or IM [36].  For that, we cultured homogenate tissues of piglets within 
the first hours of birth and did not isolate any Brucella for the most suspected tissues that 
can be colonized namely the stomach and gastric contents and the umbilicus or lungs 
[18]. Unmarked histologic lesions of the same tissue sections of piglets corroborated that 
result and therefore, we can suggest that S19 and S19 ∆vjbR did not cross the placental 
barrier while being inoculated at midgestation in pregnant swine. 
The immune response triggered by Brucella infection and vaccination was 
broadly studied in the mouse model [101]. It was established that the principal role to 
overcome the infection is played by cellular immunity and secondary the humoral 
response [102]. Experimental infection of swine with 2×107 CFU of Brucella suis biovar 
2 through the conjunctival route demonstrated a long lasting humoral response of 21 
   35 
weeks post-inoculation by Rose Bengal Test (RBT) and iELISA [103]. Immunization 
with smooth LAV elicits a humoral response toward the O-polysaccharide of the LPS 
[102,104]. In order to monitor the kinetics of humoral response elicited by vaccination in 
swine and to see if there was any correlation of immune protection that could predict 
efficacy in future studies, we studied anti-Brucella antibody responses triggered by 
vaccination using two common validated serological tests in cattle and small ruminants 
[105]. The Rose Bengal Test (RBT) which was used in Europe to screen for swine 
brucellosis [106] demonstrated that all gilts involved in this study have not previously 
been exposed to Brucella antigens eliciting a negative agglutination response at pre-
vaccination. At 2 week post-vaccination, the agglutination response was the strongest 
and started to decrease starting from 4 week and was negative at 6 week post-
vaccination. The post-vaccinal humoral reaction in this study using S19 and S19∆vjbR 
vaccine candidates seems to be transient while comparing it to experimental infection in 
swine with Brucella abortus which demonstrated an agglutination response that lasted 
more than 10 week with RBT [66]. These findings correlate with the unpublished results 
on swine vaccinated with S19 mentioning that the agglutinin response dropped rapidly 
after 4 weeks of vaccination [32]. In cattle, subcutaneous vaccination with 3x109 CFU of 
strain S19 bacteria elicited an intense agglutination with RBT at 4 weeks post-
vaccination (30 days) in 25 animals and started to decrease starting from 12 weeks post-
vaccination until it became negative at 38 weeks post-vaccination [107]. This 
demonstrates that vaccination with Brucella abortus S19 in cattle elicits a prolonged 
humoral response as opposed to swine. The iELISA which is a more sensitive test based 
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upon the reactivity toward the LPS of Brucella abortus 2308 lysate was used to confirm 
the vaccinal status of the animals but also study the kinetics of both anti-Brucella IgM 
and IgG. Our findings revealed not only that the animals were not previously into 
contact with Brucella antigens but also they had a peak at 2 weeks post-vaccination 
same as the RBT. Starting from 4 weeks, the anti-Brucella IgM demonstrated similar 
kinetics to the RBT characterized by a decrease in OD values among all the treatment 
groups and reached negativity at 6 week post vaccination. On the other hand, the IgG 
OD values peaked at 2 week post-vaccination with the vaccine candidates as well as S19 
and started to decrease starting from 4 weeks but did not reach negativity by 6 weeks. In 
comparing species vaccinated with S19, cattle demonstrated a strong total IgG response 
at 28 days post-vaccination that decreased significantly after 30 weeks post-vaccination 
[31]. In regards to the discrepancy of the results between the RBT and the anti-Brucella 
IgG iELISA, we studied the correlation between the two tests and we found out that 
there’s a substantial correlation during the 2 week and 4 week post-vaccination interval 
and a poor correlation at 6 week post-vaccination. Since the vaccination elicited a 
transient humoral response, we can easily distinguish between vaccinated animals and 
infected ones. Infected animals with Brucella will have a sustained humoral response as 
opposed to vaccinated animals with S19 or S19 ∆vjbR using the iELISA [103]. 
Practically, a screening test within 2 and 4 week post-vaccination interval can be 
introduced in the field and can serve as a DIVA strategy either while vaccinating swine 
with S19 or S19 ∆vjbR.  
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One major drawback can be encountered while using the iELISA or the RBT is 
the inability to differentiate Brucella infection or vaccination with S-LPS LAV from 
Escherichia coli O:157, some strains of Escherichia hermanni and Salmonella group N 
(O:30), Stenotrophomonas maltophila, and Vibrio cholerae O1 and especially Yersinia 
enterocolitica O:9 infection in swine [63,106,108]. To address this issue, we investigated 
the potential use of purified vjbR protein as an immunogenic marker to differentiate 
vaccinated animals from infected ones by developing a serological test that would allow 
this based on studies on humans that proved that the vjbR is highly immunogenic and 
reactive toward sera of infected humans with Brucella [52]. Hence, we expressed the 
vjbR in E. coli and in yeast. Purified vjbR from yeast was used to produce rabbit anti-
vjbR polyclonal and as a potential source of protein because we faced non-specific 
reactivity with vjbR expressed in E. coli. To characterize the vjbR protein in E. coli, 
liquid chromatography–mass spectrometry (LCMS) was employed to confirm the use of 
the purified vjbR for the DIVA serological tests. Our findings asserted with high 
confidentiality that we purified the correct protein (VjbR was identified by 19 unique 
spectra and 9 unique peptides and the peptide coverage was 38%). Additionally, anti-
histag western blot and rabbit anti-vjbR toward the vjbR demonstrated the same result. 
The vjbR recombinant protein was then used in a western blot with pre-vaccinated sera 
of all gilts and demonstrated non-specific binding to the vjbR protein with a variation of 
the intensity of the bands observed, despite multiple titrations of both primary and 
secondary antibodies.  Interestingly one animal of the control group did not react with 
the vjbR protein during pre-vaccination and 2 week post-inoculation. Post-vaccination 
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sera of the second week of all gilts were also analyzed via western blot for the reactivity 
toward the vjbR protein expressed in E. coli and demonstrated comparable results to the 
pre-vaccination.  
These findings oppose a previous study on the mouse model considering the 
usefulness of the vjbR protein as a diagnostic antigen to differentiate vaccinated mice 
with 16M ∆vjbR from ones [109]. Closely related genera of bacteria can be misidentified 
as Brucella [110,111]. Therefore, we correlated those results to the potential previous 
contact of the gilts used in this study to Brucella-like bacteria sharing identical sequence 
of the vjbR protein. We identified 3 potential bacteria with BLASTp: Ochrobactrum 
anthropi was selected because it is closely related and sometimes misidentified to 
Brucella but also it is found in the soil which increases the chances of contact of swine 
with the bacteria [110,111]. Pseudomonas aeruginosa was selected because it gives false 
negative response in low specificity serodiagnosis assays considering the fact that it 
shares the outer membrane vesicles (OMVs) with Brucella [112] and E. coli K-12 
because we suspected a residual effect from expressing the vjbR protein in E. coli and 
that is why we expressed the vjbR protein in yeast as well. Sera from S19 and S19 ∆vjbR 
encapsulated gilts that demonstrated intense cross-reactivity with the vjbR protein at the 
pre-vaccination were exposed to these 3 bacterial lysates. No reactivity toward 
Ochrobactrum anthropi, Pseudomonas aeruginosa and E. coli K-12 was noticed. As it 
was shown in the case of BP26, an immunogenic protein of B. melitensis, sera from 
Brucella-free sheep and B. melitensis infected sheep cross-reacted with the protein. A 
substitution of amino acids from the entire BP26 while keeping the region of BP26 
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between amino acids 55 and 152 allowed to avoid the false positive reaction of Brucella-
free sheep sera [113].  
Further investigations using the vjbR protein for epitope mapping [114] will be 
undertaken to develop a reliable serological diagnostic tool that distinguishes infected 
animals from vaccinated ones and therefore assesses the DIVA capability of the S19 
∆vjbR vaccine candidate in natural hosts. 
Overall, the vaccine candidates proved to be safe and did not induce any 
undesirable side effect. Vaccination with S19∆vjbR vaccine candidates triggered a 
transient anti-Brucella humoral response comparable to the one elicited by S19 in swine. 
For that, an efficacy study will be undertaken to evaluate the protective aspect of the 
vaccine candidate under the two formulations. The variable cross-reactivity observed in 
pre-vaccinated sera with the vjbR protein compromised the DIVA ability of the vaccine 
candidates in this study. Therefore, an epitope mapping is essential to identify the 
protein binding site that causes the non-specific reactivity and substitute it to develop a 
DIVA serological tool using the S19 ∆vjbR vaccine candidate. 
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APPENDIX A 
 
 
 
 
Fig. 1. Average rectal temperature in gilts vaccinated with live attenuated vaccine 
formulations. Results are expressed as mean of weekly body temperatures of each group. 
Temperature above 38.8 ºC is considered fever. Statistical analysis was performed using 
the one-way analysis of variance (ANOVA) test and Dunn’s multiple comparisons. No 
significant difference was observed between groups 
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Fig. 2. Histological analysis of spleen, liver, lung and uterus from gilts inoculated with 
1) S19, 2) S19 ΔvjbR encapsulated, 3) S19 ΔvjbR unencapsulated and 4) Empty capsule 
(control) at 5 days post-delivery. None of the gilts inoculated with the different vaccine 
strains had any significant histopathological changes in the major organs. 
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Fig. 3.  Anti-Brucella specific IgM and IgG responses in serum samples from individual 
gilts immunized with different B. abortus vaccinates and individual gilts from control 
group. Results are expressed as mean of individual sera OD values. Statistical analysis 
was done by comparing the mean of all groups between each other at different time 
points by using the two-way analysis of variance (ANOVA) test and Tukey’s multiple 
**
** **
** ** 
61 
comparisons. **Values are statistically different (P<0.01) from the control at different 
time points. 
Fig. 4. Histological analysis of spleens, livers, lungs (10x) and umbilical cords (4x) 
from piglets of gilts inoculated with 1) S19, 2) S19 ΔvjbR encapsulated, 3) S19 ΔvjbR 
unencapsulated and 4) Control. 
62 
Fig. 5. Immunodetection of the vjbR protein by Western blot analyses. (A) Anti-histag 
specific Western blot. (B) vjbR purified protein reactivity with rabbit anti-vjbR 
polyclonal antibody. The purified vjbR protein was expressed in E. coli. The reacting 
vjbR protein size is estimated at 〜40 kDa 
A B 
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Fig. 6. Immunoreactivity of pre-vaccinated and 2nd week post-vaccinated gilt sera with 
S19, S19 ∆vjbR encapsulated or unencapsulated and empty capsule to the vjbR protein. A 
dark band is showing at the vjbR protein size (〜40 kDa) at pre-vaccination with variable 
intensity. 
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Fig. 7. Reactivity of rabbit anti-vjbR, pre-vaccinated sera of S19 and S19 ∆vjbR gilts 
with Ochrobactrum anthorpi, Pseudomonas aeruginosa and E. coli K-12. VjbR purified 
protein exposed to rabbit anti-vjbR was used as a positive control. 
 
 
 
 
 
 
 
 
 
Pseudomonas aeruginosa  
 VjbR 
Ochrobactrum anthorpi 
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APPENDIX B 
 
Table 1 
Litter size and number of births from pregnant gilts after farrowing. 
 
 
p-value of 0.9 
Abortion is defined by expulsion of dead fetuses prior to normal delivery (normal delivery 
is estimated to occur at 115 days of pregnancy in swine). 
Post-partum deaths are defined by the normal delivery of either hypoxic (non-breathing) 
piglets classified as stillbirths or traumatic deaths by crushing.  
 
 
 
 
 
Group Animal 
Number 
# of 
piglets 
per gilt 
Total 
litter 
size 
Litter size 
(Mean ± 
SD) 
# of 
abortions 
 # of 
post-
partum 
deaths  
 # of 
stillbirths 
S19 1 13 49 12.25 ± 2.5 0/49 3 1/6 
(16.66%) 
2 12    1  
3 9    2  
4 15    0  
S19 ΔvjbR 
encapsulated 
1 13 49 12.25 ± 0.96 0/49 1 0/3 
2 12    2 (0%) 
3 11    0  
4 13    0  
S19 ΔvjbR 
unencapsultated 
1 12 45 11.25 ± 2.99 0/45 1 0/5 
2 8    1 (0%) 
3 15    1  
4 10    2  
Control 1 11 38 12.7± 3.79 0/38 10 2/12 
(16.66%) 
2 10    0  
3 17    2  
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Table 2 
Vaccine shedding in pregnant gilts through vaginal secretions after vaccination. 
 
 
Group Animal 
Number 
Pre-
vaccination 
2 week post 
vaccination 
4 week post 
vaccination 
6 Week 
post 
vaccination 
S19 1 - - - - 
2 - - - - 
3 - - - - 
4 - - - - 
S19 ΔvjbR 
encapsulated 
1 - - - - 
2 - - - - 
3 - - - - 
4 - - - - 
S19 ΔvjbR 
unencapsultated 
1 - - - - 
2 - - - - 
3 - - - - 
4 - - - - 
Control 1 - - - - 
2 - - - - 
3 - - - - 
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Table 3 
Bacterial colonization in multiple tissues from gilts immediately after delivery (7 week 
post-vaccination). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group Blood Liver Lung Spleen Mammary 
LN 
Inguinal 
LN      
Uterus Placenta 
 
S19 
 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
S19 ΔvjbR 
encapsulated 
- - - - - -       -         - 
S19 ΔvjbR 
unencapsultated 
 
- - - - - - - - 
Control (Empty 
capsule) 
- - - - - - - - 
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Table 4 
Rose Bengal screening in vaccinated gilts at 0, 2, 4 and 6 week post-vaccination. 
 
 
Group Animal 
Number 
Pre-
vaccination 
2 week 
post 
vaccination 
4 week 
post 
vaccination 
6 Week 
post 
vaccination 
S19 1 - +++ ++ - 
2 - +++ n/a - 
3 - +++ + - 
4 - +++ ++ - 
S19 ΔvjbR 
encapsulated 
1 - +++ + n/a 
2 - ++ ++ - 
3 - ++ - - 
4 - ++ n/a - 
S19 ΔvjbR 
unencapsultated 
1 - +++ + - 
2 - ++++ +++ n/a 
3 - ++++ +++ - 
4 - - - - 
Control 1 - - - - 
2 - - - n/a 
3 - - - - 
Samples from animals represented by n/a indicate gilts that the collection of blood was 
not available  
 
++++/+++ strong agglutination 
++ mild agglutination 
 + weak agglutination  
 - no agglutination 
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Table 5 
Comparison of the iELISA and RBT using Bayesian analysis for vaccination screening.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Estimates Pre-
vaccination 
2 Week Post-
vaccination 
4 Week Post-
vaccination 
6 Week Post-
vaccination 
Kappa ‘κ’ 
 
1 0.8 0.65 0 
Agreement Perfect Substantial Substantial Poor 
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Table 6 
Vertical colonization of piglet major tissues immediately after delivery. 
 
 
 
 
 
 
 
 
 
 
 
 
Group Total 
litter 
size 
Liver Lung Spleen Umbilicus Kidney Gastric 
contents 
S19 
 
49 0/49 0/49 0/49 0/49 0/49 0/49 
S19 ΔvjbR 
encapsulated 
 
49 0/49 0/49 0/49 0/49 0/49 0/49 
S19 ΔvjbR 
unencapsultated 
 
45 0/45 0/45 0/45 0/45 0/45 0/45 
Control (Empty 
capsule) 
38 0/38 0/38 0/38 0/38 0/38 0/38 
